DRESS syndrome; Drug Reaction with Eosinophilia and Systemic Symptoms: A case report and literature review
DOI:
https://doi.org/10.66344/jpad.v34i4.2949Keywords:
DRESS syndrome, RegiSCAR criteria, Leflunamide, PiroxicamAbstract
DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome is a severe, idiosyncratic, T-cell mediated hypersensitivity reaction of drugs characterised by fever, skin manifestations, lymphadenopathy, hematological abnormalities and involvement of internal organs that develops 2-8 weeks after intake of the culprit drug. Its pathophysiology includes genetic susceptibility, defect in the metabolic pathway of drugs and reactivation of human herpes viruses (HHVs). The interaction of these pathogenetic factors is responsible for cutaneous and systemic manifestations of DRESS syndrome. Many cases of DRESS syndrome have been reported globally but to the best of our knowledge DRESS syndrome has not been reported in Pakistan todate. We report a case of DRESS syndrome in which the suspected drug was leflunamide or piroxicam.
References
1. Agrawal T, Haritha T, Rthore PK, Suganita. Study of cutaneous adverse reactions to drugs. J Pak Assoc Dermatol. 2022;32(1):22-6.
2. Amiri R, Mostafai M, Mohammad S, Khalili M, Aflatoonian M. Evaluation of demographic and clinical features of the patients admitted with drug reactions. J Pak Assoc Dermatol. 2023;33(2):619-23.
3. Hoque ME, Khan MAL, Khan MSI, Hoque MM, Hossain N. Severe cutaneous adverse reactions in a local hospital setting in Bangladesh: A 5-year retrospective study. J Pak Assoc Dermatol. 2023;33(3):912-9.
4. Evanti AM, Widhiati S. The efficacy of oral cyclosporine in a patient with drug reaction with eosinophilia and systemic symptoms probably due to cefadroxil. J Pak Assoc Dermatol. 2023;33(2):754-8.
5. Walsh S, Lee HY, Creamer D. Severe Cutaneous Adverse Reactions to Drugs. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. 9th(ed). West Sussex: Wiley Blackwell; 2016.P. 119.4-119.11.
6. Calle AM, Aguirre N, Ardila JC, Villa RC. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J. 2023;16(3):100673.
7. Manieri E, Dondi A, Neri I, Lanari M. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: a narrative review. Front Med. 2023;10:1108345.
8. Cabanas R, Ramirez E, Sendagorta E, Alamar R, Barranco R, Blanca-Lopez N, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-53.
9. May C, Fleckman P, Brandling-Bennett HA, Cole B, Sidbury R. Lichenoid Drug Eruption with Prominent Nail Changes Due to Leflunamide in a 12-Year-Old Child. Pediatr Dermatol. 2017;34(4):225-226.
10. Marzano AV, Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunamide- induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus. 2008;17(4):329-31.
11. Schmutz JL, Barbaud A, Trechot P. Leflunamide et syndrome de Lyell. Ann Dermatol Venereol. 2009;136(4):395.
12. Shastri V, Betkerur J, Kushalappa PA, Savita TG. Severe cutaneous adverse drug reaction to leflunamide: A report of five cases. Indian J Dermatol Venereol Leprol. 2006;72(4):286-289.
13. Vashish D, Tripathy MD, Sandhu S, Kothari R, Vashisht S, Hegde A. Leflunamide Induced Drug Reaction with Eosinophilia and Systemic Symptoms: A Lesser Known Entity. Indian J Rheumatol.2020;15(3):242-4.
14. Rao S, Sunkara A, Srivastava N, Sampat P, Ramos C, Albert E. An Uncommon Presentation of DRESS Syndrome Secondary to Leflunamide Use: A Case Report. J Investig Med High Impact Case Rep. 2021;9:1-4.
15. Gayfield S, Busken J, Mansur S. Recurrent Leflunamide-Induced Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) Syndrome Despite Prolonged Steroid Taper: A Case Report. Cureus. 2022;14(9): e29319.
16. Fatima M, Azimi SS, Ashwini S, Radhakrishna MH. Leflunamide induced Atypical DRESS: A Case Report and Literature Review. Mediterr J Rheumatol. 2023;34(1):91-6.
17. Vasconcelos C, Magina S, Quirino P, Barros MA, Mesquita-Guimaraes J. Cutaneous drug reactions to piroxicam. Contact Dermatitis. 1998;39(3):145.
18. Bizid S, Haddad W, Abdallah HB, Ghanem M, Bouali R, Abdelli N. Severe acute hepatitis induced by a DRESS syndrome to piroxicam. Tunis Med. 2014;92(6):417.
19. Young AJ, Torres SM, Koch SN. Probable cutaneous adverse drug reaction to piroxicam in a cat. JFMS Open Rep. 2018;4(2):2055116918786598.
20. Gomez VR, Molero AR, Amarilla IP, Frances SC, Rubio ERD, Catalan M, Vanaclocha F, Colina F. DRESS syndrome secondary to ibuprofen as a cause of hyperacute liver failure. Rev Esp Enferm Dig. 2014;106(7):482-6.
21. Sah SK, Shakya B, Shariff A, Babu MS, Ramaswamy S, Ramesh M, Niharika P, Dhurappanavar SN. Aceclofenac-Induced Drug Reaction with Eiosinophilia and Systemic Symptoms Syndrome. J Pharmacol Pharmacother. 2021;12:144-6.
22. Charfi O, Aouinti I, Zaiem A, Lakhoua G, Aidli SE, Kastalli S. Diclofenac induced drug rash with eosinophilia and systemic symptoms. Therapie. 2018;73(6):551-3.
23. Sevabharathi A, Meena NS, Kumar A, Kumar N, Kumar K. Diclofenac induced DRESS syndrome. Sch J Med Case Rep. 2016;4(4):281-3.
24. Sasi S, Altrarawneh H, Petkar MA, Nair AP. Drug Reaction with Eosinophilia and Systemic Symptoms to Naproxen: A Case Report and Literature Review. Case Rep Acute Med. 2020;3:63-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Bushra Mehmood, Alizah Tariq Zaman, Tariq Zaman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
